The tyranny of non-inferiority trials.

Autor: Tannock IF; Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada; Optimal Cancer Care Alliance, Ann Arbor, MI, USA. Electronic address: ian.tannock@uhn.ca., Buyse M; IDDI (International Drug Development Institute), Louvain-la-Neuve, Belgium; I-BioStat, Hasselt University, Hasselt, Belgium., De Backer M; IDDI (International Drug Development Institute), Louvain-la-Neuve, Belgium., Earl H; Department of Oncology, University of Cambridge, Cambridge, UK., Goldstein DA; Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Davidoff Cancer Center, Rabin Medical Center, Israel; Clalit Health Services, Tel Aviv, Israel; Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Ratain MJ; Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA., Saltz LB; Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Sonke GS; Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, Netherlands; University of Amsterdam, Amsterdam, Netherlands., Strohbehn GW; Optimal Cancer Care Alliance, Ann Arbor, MI, USA; Veterans Affairs Center for Clinical Management Research, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Division of Oncology and Lung Precision Oncology Program, University of Michigan Division of Hematology/Oncology, Rogel Cancer Center, Institute for Health Policy and Innovation, and Center for Global Health Equity, Ann Arbor, MI, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Oct; Vol. 25 (10), pp. e520-e525.

Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system.

Autor: Bryant AK; Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA; Department of Radiation Oncology, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Lung Precision Oncology Program, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Lewy JR; University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA., Bressler RD; School of International and Public Affairs, Columbia Climate School, and Center for Environmental Economics and Policy, Columbia University, New York, NY, USA., Chopra Z; University of Michigan Medical School, University of Michigan, Ann Arbor, MI, USA; Department of Economics, University of Michigan, Ann Arbor, MI, USA., Gyori DJ; Division of Oncology, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA., Bazzell BG; Division of Oncology, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA., Moeller JA; Division of Oncology, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA., Jacobson SI; Yale College, New Haven, CT, USA., Fendrick AM; Division of General Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; Center for Value-Based Insurance Design, University of Michigan, Ann Arbor, MI, USA., Kerr EA; Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA; Division of General Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA., Ramnath N; Lung Precision Oncology Program, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Division of Oncology, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA., Green MD; Department of Radiation Oncology, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Lung Precision Oncology Program, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, USA., Hofer TP; Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Division of General Internal Medicine, University of Michigan, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; Center for Global Health Equity, University of Michigan, Ann Arbor, MI, USA., Vaishnav P; School for Environment and Sustainability, University of Michigan, Ann Arbor, MI, USA., Strohbehn GW; Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA; Lung Precision Oncology Program, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Division of Oncology, Charles S Kettles VA Medical Center, Ann Arbor, MI, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA; Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA; Center for Global Health Equity, University of Michigan, Ann Arbor, MI, USA. Electronic address: gstrohbe@umich.edu.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2024 Jun; Vol. 25 (6), pp. 802-810.

'Contribution of component' and the perioperative immune-checkpoint inhibitor precedent.

Autor: Strohbehn GW; Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA. gstrohbe@umich.edu.; Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA. gstrohbe@umich.edu.; Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. gstrohbe@umich.edu., Gyawali B; Department of Oncology, Division of Cancer Care and Epidemiology, Queen's University, Kingston, Ontario, Canada.

Publikováno v: Nature reviews. Clinical oncology [Nat Rev Clin Oncol] 2024 Apr; Vol. 21 (4), pp. 249-250.

Special designations and the US Food and Drug Administration's "dual mandate".

Autor: Strohbehn GW; Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA.; Institute for Health Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Ratain MJ; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA.

Publikováno v: Journal of the National Cancer Institute [J Natl Cancer Inst] 2024 Feb 08; Vol. 116 (2), pp. 177-179.

Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?

Autor: Ratain MJ; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois, USA. Electronic address: mratain@bsd.uchicago.edu., Strohbehn GW; Veterans Affairs Center for Clinical Management Research and Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan, USA.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2023 Nov; Vol. 194, pp. 113349. Date of Electronic Publication: 2023 Sep 20.